These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3814736)

  • 1. The calculation of probabilities in rejecting bioequivalence.
    Yee KF
    Biometrics; 1986 Dec; 42(4):961-5. PubMed ID: 3814736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian analysis of the two-period crossover design for clinical trials.
    Grieve AP
    Biometrics; 1985 Dec; 41(4):979-90. PubMed ID: 3830262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relative efficiency of Zelen's prerandomization design for clinical trials.
    Anbar D
    Biometrics; 1983 Sep; 39(3):711-8. PubMed ID: 6652204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exact one-sided confidence limits for the difference between two correlated proportions.
    Lloyd CJ; Moldovan MV
    Stat Med; 2007 Aug; 26(18):3369-84. PubMed ID: 17315269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Event-tree analysis with imprecise probabilities.
    You X; Tonon F
    Risk Anal; 2012 Feb; 32(2):330-44. PubMed ID: 22053780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The parasite capacity of the host population].
    Kozminskiĭ EV
    Parazitologiia; 2002; 36(1):48-59. PubMed ID: 11965643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size for two-stage studies with maintenance therapy.
    Feng W; Wahed AS
    Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On estimating the difference between two probabilities, with special reference to clinical trials.
    Anbar D
    Biometrics; 1983 Mar; 39(1):257-62. PubMed ID: 6871355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian approach to bioequivalence for the 2 x 2 changeover design.
    Selwyn MR; Dempster AP; Hall NR
    Biometrics; 1981 Mar; 37(1):11-21. PubMed ID: 7018605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variance estimation in clinical studies with interim sample size re-estimation.
    Miller F
    Biometrics; 2005 Jun; 61(2):355-61. PubMed ID: 16011681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The crossover experiment for clinical trials.
    Brown BW
    Biometrics; 1980 Mar; 36(1):69-79. PubMed ID: 7370374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.